ロード中...
Management of immune checkpoint inhibitor‐related rheumatic adverse events
Immune checkpoint inhibitors (ICIs), which target the programmed cell death receptor‐1 and cytotoxic T lymphocyte‐associated antigen‐4 signaling pathways, represent remarkable breakthroughs in cancer treatment and have improved survival among patients with a variety of malignancies. However, the wid...
保存先:
| 出版年: | Thorac Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons Australia, Ltd
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6938753/ https://ncbi.nlm.nih.gov/pubmed/31762209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13249 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|